Massive Bio Makes Inaugural Strategic Investment in Rivvi to Build an End-to-End AI Engagement Infrastructure for Healthcare

Massive Bio, Inc., a global precision oncology and AI-enabled real-world data company, today announced at Ai4 2026 that it has made a strategic investment in Rivvi AI, Inc., an agentic AI infrastructure company for healthcare and life sciences. The transaction is Massive Bio's first strategic investment in another AI company. It builds on the companies' existing work across oncology trial programs and pairs capital with a shared plan to connect clinical intelligence, personalized patient outreach, and human-led navigation. Financial terms were not disclosed.

An estimated 3% to 5% of adults with cancer in the United States enroll in therapeutic clinical trials. Massive Bio addresses the intelligence layer by structuring clinical and biomarker data, identifying relevant trials, and supporting navigation. Rivvi adds the action layer: AI agents that turn each match into a governed, auditable workflow, reaching patients, surfacing barriers, coordinating next steps, and escalating to the appropriate human team.

Rivvi is an agentic AI workspace for healthcare operations. A single orchestrator agent learns an organization's programs, policies, and systems, composes the right program, and runs it end-to-end, including outreach, barrier discovery, scheduling, consent capture, workflow triggers, and defined human-escalation paths. Every action is personalized, governed, and auditable, and the platform compounds as it learns each organization.

The design preserves clear boundaries. Rivvi's AI does not diagnose, prescribe, or override clinical judgment. Each organization can configure policies, escalation rules, access controls, and audit trails for its workflows. Rivvi's platform is HIPAA compliant and SOC 2 Type II, with business associate agreements available, and supports deployment without requiring a new electronic medical record integration.

“Massive Bio brings the oncology intelligence, evidence base, global reach, and operational network to identify where action matters most. Rivvi brings the infrastructure to conduct and govern personalized patient conversations at scale. Their investment accelerates our ability to serve life sciences and complex-care programs, and together we can help healthcare organizations reach more patients with the context, timing, and human support needed to act,” said Nathan Hayman, Co-Founder and Chief Executive Officer of Rivvi.

Rivvi has powered more than two million patient interactions across more than 500,000 patients and serves health systems, payers, pharmacies, PBMs, and life sciences organizations.